Skip to main content

Posts

Stop Guessing What a Stock Is Worth

FAST Graphs helps investors visualize a company’s earnings, valuation, dividends, and historical performance in one clear research platform. Compare price with fundamentals, identify potential overvaluation or undervaluation, and make decisions with greater confidence.

Research the business behind the stock.

Explore FAST Graphs Today

Disclosure: This advertisement may contain an affiliate link. I may earn a commission at no additional cost to you.

Featured post

BlackRock and the ETF Revolution: What Happens When Scale Becomes the Moat?

When I first began paying attention to exchange-traded funds, I viewed them as financial plumbing. They were useful, efficient, and not particularly exciting. An ETF allowed me to buy a basket of securities without selecting every stock or bond myself, and that seemed like a sensible improvement over building a portfolio one company at a time. What I did not fully appreciate was that the plumbing would eventually become some of the most valuable infrastructure in global finance. ETFs have moved from the margins of investing to the center of it. They sit in retirement accounts, brokerage portfolios, institutional strategies, model portfolios, robo-advisory platforms, and short-term trading systems. They are used by people investing $50 from a paycheck and institutions moving billions of dollars before lunch. BlackRock, through its iShares franchise, has become one of the clearest beneficiaries of this transformation. By the end of 2025, BlackRock had approximately $14 trillion in total ...
Post a Comment
Read more
Recent posts

Biotech Without the Binary Bet? Why ACADIA Is an Unusual Pharmaceutical Investment

I have a complicated relationship with biotech stocks. I love the science, the unmet medical needs, and the possibility that one successful medicine can change both patients’ lives and a company’s value. I am less fond of waking up to discover that a clinical trial missed its primary endpoint and half my investment has evaporated before I have located the coffee. That is the biotech bargain. Investors are invited to study molecular targets, trial designs, competitive landscapes, safety profiles, and regulatory pathways. Then a press release arrives at 7:00 a.m. and reduces years of careful analysis to one merciless word: met or missed. This is why ACADIA Pharmaceuticals catches my attention. ACADIA, which trades under the ticker ACAD, does not fit neatly into the familiar small-biotech stereotype. It is not a pre-revenue company living from financing round to financing round while asking shareholders to remain patient for another eighteen months. It already sells two FDA-approved medic...
Post a Comment
Read more

Beyond the iPhone: Where Apple’s Next Trillion Dollars of Value Could Come From

Whenever I hear someone ask what Apple will do after the iPhone, I think the question begins in the wrong place. It assumes Apple needs to invent another product as culturally dominant and financially powerful as the iPhone before the company can create its next trillion dollars of market value. I do not believe it does. Apple is no longer a company waiting for one device to save it. It is a platform spread across billions of active devices, supported by custom silicon, software, subscriptions, payments, wearables, health data and an extraordinarily loyal customer base. The iPhone remains the center of that system, but the next phase of Apple’s value may come from making every person inside the system worth a little more—not from discovering a completely new population overnight. As of September 14, 2026, Apple’s market capitalization was approximately $4.9 trillion. Adding another trillion would represent an increase of roughly 20%. That is a serious challenge, especially with the sto...
Post a Comment
Read more

BEN’s Dividend Is Attractive—but What Is the Market Trying to Tell Investors?

Franklin Templeton’s income looks dependable. The harder question is whether the business underneath it is finally turning a corner. I have a weakness for dividend stocks. There is something deeply satisfying about owning a company that sends me cash without requiring me to sell anything, predict the next market craze, or pretend I understand why a cryptocurrency named after a cartoon animal gained 40% before breakfast. But a dividend can be seductive in exactly the wrong way. A large yield can look like a welcome mat when it is actually caution tape. It can make a struggling company appear generous when the market is quietly pricing in stagnant earnings, weak growth, or a future cut. A dividend tells me what management intends to pay. The stock price tells me what investors think that promise is worth. That brings me to Franklin Templeton, which still trades under the ticker BEN following the company’s August 2026 corporate name change from Franklin Resources. At a recent price near $...
Post a Comment
Read more

Azure’s AI Infrastructure Buildout Could Reshape Microsoft’s Profit Margins

For years, Microsoft trained investors to think of cloud computing as one of capitalism’s more elegant machines. Build the platform, fill the data centers, sell recurring access, and watch software economics spread across an enormous customer base. It was not effortless, but it looked wonderfully scalable. Each additional workload could ride on infrastructure Microsoft had already built, while subscription revenue arrived with the dependable rhythm of a direct debit nobody in accounting wanted to cancel. Then artificial intelligence showed up carrying a shopping list. The list included graphics processors, central processing units, custom silicon, networking equipment, cooling systems, power contracts, land, concrete, backup generators, fiber, and data centers large enough to make an airport terminal feel intimate. Suddenly, the cloud business that investors loved for its software-like margins began consuming capital with the appetite of a heavy industrial project. I do not view this a...
Post a Comment
Read more